Drug Discovery
  • Target deconvolution
  • Target validation
  • Mode of action analysis
  • Toxicity profiling
Clinical Proteomics
  • Translational research
  • Companion diagnostics
  • Complex biomarker signatures
  • Drug response prediction
Disease and Systems Biology
  • Signal transduction
  • Disease mechanisms
  • Mechanistic biomarkers
  • Multi-omics integration
Accelerating drug and biomarker discovery

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies.

Founded by leading proteomics researchers, the company has a track record in delivering significant collaborations with top pharmaceutical and biotechnology companies.

We provide and develop proteome-wide assays that work with native proteins in a physiological setting and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers.

OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.

Latest News
Nov. 1 - Feb. 28, 2019
Kinase inhibitors are an important class of drugs that block protein kinases involved in diseases such as cancer and inflammatory ...
März 7 - März 7, 2019
Our CEO, Hannes Hahne, will give a talk on "Proteomics for Target and Pathway Deconvolution" at the ELRIG Forum in Darmstadt, Germ...
März 7 - März 9, 2019
Numerous colleagues will be present at the EMBL conference "Proteomics in Cell Biology and Disease Mechanisms" 2019 in Heidelberg,...

Scientific excellence in proteomics, computational biology and drug discovery

Read More »

Collaborations with leading academic and industry partners

Read More »

Further informations on job openings

Read More »